Asahi Kasei Pharma Develops Osteoporosis Patch Drug With Global Market In Mind
This article was originally published in PharmAsia News
Asahi Kasei Pharma Co. Ltd plans to develop and market the first transdermal peptide agent for osteoporosis in Asia.
You may also be interested in...
Chi-Med’s surufatinib has come up trumps in a second trial in neuroendocrine tumors, after the monitoring committee recommended an early halt following achievement of its PFS target in the pancreatic setting.
Oncology R&D isn’t waning, but investment in neurology and psychiatry drug development are paying off in new drug approvals. Rapid growth in CDER non-malignant hematology approvals reflects longer, broader trend toward orphan drugs.
We clean out your Martin Luther King Day inbox so you don't have to.